ReAx Biotechnologies
Pre-clinical biotechnology company using chemoproteomic drug discovery to develop novel therapies for oncology and immunology by targeting previously undruggable proteins.
Website
https://www.reaxbio.comLocation
Chicago, Illinois, USA
Founded
2021
Investors
1
Categories
biotech, chemoproteomics, drug-discovery, oncology, immunology
Notes
ReAx Biotechnologies is a pre-clinical biotechnology company focused on chemoproteomic drug discovery for oncology and immunology. The company's platform enables the identification and targeting of previously undruggable proteins, expanding the universe of potential therapeutic targets.
ReAx was spun out from the University of Chicago and is developing a pipeline of novel therapeutics using its proprietary chemoproteomics approach.
Team
- Ray Moellering, Ph.D. - Founder & Chief Executive Officer
Additional Research Findings
- Founded in 2021 in Chicago, Illinois
- Portfolio company of Portal Innovations
- Stage: Pre-clinical
- University spinout: University of Chicago
- Proprietary chemoproteomics platform
- Focus on oncology and immunology drug discovery
- Targeting previously undruggable proteins
- Part of growing targeted protein modulation space
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Portal Innovations | US | biotech-focused | - | 13 |